CNS pipeline · person
Paul Kelly, MBA
Chief Operating Officer of Relmada Therapeutics (effective January 1, 2025) and a Director since November 2015. He has more than 25 years in the biotechnology sector as an equity analyst, consultant, and investor, including roles at Mabon Securities, UBS, and Merrill Lynch, and was named to the inaugural Fortune Magazine All-Star Analyst Team in 2000. He holds an A.B. in biochemistry from Brown University and an MBA from the University of Rochester.
- 1 company
Courtesy Relmada Therapeutics
Current roles
- Relmada Therapeutics, Inc.Chief Operating Officer · Executive2025–present
- Relmada Therapeutics, Inc.Director · Board2015–present
Appears with
People sharing a company with Paul.
- Charles Ence · Relmada Therapeutics, Inc.
- Charles J. Casamento · Relmada Therapeutics, Inc.
- Fabiana Fedeli · Relmada Therapeutics, Inc.
- John Glasspool · Relmada Therapeutics, Inc.
- Maged Shenouda · Relmada Therapeutics, Inc.
- Max Kates · Relmada Therapeutics, Inc.
- Raj S. Pruthi · Relmada Therapeutics, Inc.
- Sergio Traversa · Relmada Therapeutics, Inc.
- Yair Lotan · Relmada Therapeutics, Inc.
People and affiliation data assembled from public company disclosures, SEC filings, and conference materials — every record source-cited under psychiatrist-authored guardrails.